Development and validation of a disulfidptosis-related genes signature for predicting outcomes and immunotherapy in acute myeloid leukemia
Our study provides insights into DRG prognoses and immunomodulation, establishing a robust 6-gene risk model for predicting AML outcomes that may enhance precision medicine and treatment strategies.
Authors
- Xusheng Wu (ORCID: https://orcid.org/0009-0001-2651-0813)
- Mingwei Wang (ORCID: https://orcid.org/0000-0002-0799-3311)
- Yiming Pan (ORCID: https://orcid.org/0009-0006-4318-813X)
- Han Gong (ORCID: https://orcid.org/0000-0001-9835-1551)
- Jing Liu (ORCID: https://orcid.org/0000-0002-0958-5506)
- Ying Zhang (ORCID: https://orcid.org/0000-0002-0002-3064)
- Ling Li (ORCID: https://orcid.org/0000-0001-5194-0391)
- Xiaofeng He (ORCID: https://orcid.org/0000-0001-8255-1874)
- Zhong Liu (ORCID: https://orcid.org/0000-0003-4096-3170)
Institutions
- Central South University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Second Xiangya Hospital of Central South University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-04-04
- DOI
- https://doi.org/10.3389/fimmu.2025.1513040
- Citations
- 3
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 5.31